// App-Quantinova.ai

: Respiratory safety profile of indacaterol/glycopyrronium (IND/GLY) versus salmeterol/fluticasone (SFC): results from the FLAME study

Researchers

Presenter

  • Jadwiga Wedzicha

Principal Investigators

  • Claus F. Vogelmeier

  • Tim Ayers

  • Petter Olsson

  • Francesco Patalano

  • Chau Thach

  • Robert Fogel

  • Donald Banerji

Medical Centers

  • National Heart and Lung Institute, Imperial College London, London, United Kingdom

  • Pulmonary and Critical Care Medicine, Philipps–Universität Marburg, Marburg, Germany

  • Novartis Pharmaceuticals Corporation East Hanover NJ United States

  • Novartis Sverige AB, Kista, Sweden

  • Novartis AG, Basel, Switzerland

Locations

  • United Kingdom

  • Germany

  • United States

  • Sweden

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • salmeterol + fluticasone

  • Seebri Breezhaler

  • Fluticasone

  • Fluticasone furoate

  • indacaterol

  • Salmeterol Xinafoate

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved